Prescription of antihypertensive agents to haemodialysis patients: Time trends and associations with patient characteristics, country and survival in the DOPPS

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2809-2816

  Lopes, Antonio Alberto ^a   Bragg Gresham, Jennifer L ^b   Ramirez, Sylvia P B ^b   Andreucci, Vittorio E ^c   Akiba, Takashi ^d   Saito, Akira ^e   Jacobson, Stefan H ^f   Robinson, Bruce M ^b   Port, Friedrich K ^b   Mason, Nancy A ^g   Young, Eric W ^h  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f DANDERYD HOSPITAL   (Sweden)

^g UNIVERSITY OF MICHIGAN   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antihypertensive agents; Cardiovascular; Haemodialysis; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR BLOCKER; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERIPHERAL BLOCKER; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HEMODIALYSIS; HUMAN; ITALY; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 69249118530     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp212     Document Type: Article

References (33)

1. Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401-1409
2. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975
3. Turnbull F, Neal B, Algert C et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419
4. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
5. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002; 360: 752-760
6. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592
7. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005; 366: 1545-1553
8. Haim M, Shotan A, Boyko V et al. The Bezafibrate Infarction Prevention (BIP) Study Group. Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III. Am J Cardiol 1998; 81: 1455-1460
9. Bunch TJ, Muhlestein JB, Bair TL et al. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am J Cardiol 2005; 95: 827-831
10. Cheung AK, Sarnak MJ, Yan G et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65: 2380-2389
11. Bloembergen WE, Port FK, Mauger EA et al. Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol 1994; 5: 1231-1242
12. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003; 16: 111-117
13. Tonelli M, Bohm C, Pandeya S et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001; 37: 484-489
14. Roy P, Bouchard J, Amyot R et al. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006; 48: 645-651
15. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol 2008; 3: 1415-1422
16. Young EW, Goodkin DA, Mapes DL et al. The dialysis outcomes and practice patterns study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57(Suppl 74): S74-S81
17. Pisoni RL, Gillespie BW, Dickinson DM et al. The dialysis outcomes and practice patterns study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7-15
18. Klein JP, Moeschberger ML. Survival Analysis Techniques for Censored and Truncated Data. New York: Springer, 1997, 417
19. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998; 19: 17-34
20. Brookhart MA, Wang PS, Solomon DH et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275
21. Stukel TA, Fisher ES, Wennberg DE et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297: 278-285
22. Carr AA, Kowey PR, Devereux RB et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96: 1530-1536
23. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180
24. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110: 2618-2626
25. Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314
26. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; x41: 1438-1444
27. Griffith TF, Chua BS, Allen AS et al. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003; 42: 1260-1269
28. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745
29. Yusuf S, Sleight P, Pogue J et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153
30. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
31. Kowey PR, Dickson TZ, Zhang Z et al. Losartan and end-organ protection-lessons from the RENAAL study. Clin Cardiol 2005; 28: 136-142
32. Sarkar SR, Kotanko P, Levin NW. Interdialytic weight gain: implications in hemodialysis patients. Semin Dial 2006; 19: 429-433
33. Santos SF, Peixoto AJ. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 522-530